A9102
AH13205
≥98% (HPLC), oil
Synonym(s):
trans-2-(4-(1-Hydroxyhexyl)phenyl-5-oxocyclopentaneheptanoic acid
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C24H36O4
CAS Number:
Molecular Weight:
388.54
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI key
XMQKDOCUWFCMEJ-JAZPPYFYSA-N
SMILES string
CCCCCC(O)c1ccc(cc1)[C@H]2CCC(=O)[C@@H]2CCCCCCC(O)=O
InChI
1S/C24H36O4/c1-2-3-6-10-22(25)19-14-12-18(13-15-19)20-16-17-23(26)21(20)9-7-4-5-8-11-24(27)28/h12-15,20-22,25H,2-11,16-17H2,1H3,(H,27,28)/t20-,21-,22?/m1/s1
assay
≥98% (HPLC)
form
oil
color
pale yellow
solubility
DMSO: >10 mg/mL
originator
GlaxoSmithKline
storage temp.
−20°C
General description
AH13205 is EP2 prostanoid receptor agonist. There are five types of prostanoid receptors, which are classified based on sensitivity to the five naturally-occuring prostanoid ligand. The EP type of receptor is further divided into four subgroups – EP1, EP2, EP3 and EP4. EP2 activation results in vascular, bronchial and reproductive smooth muscle relaxation.
Biochem/physiol Actions
AH13205 is a selective, low potency agonist for the EP2 receptor. AH13205 has been shown to compete with Prostaglandin E2 (PGE2) for binding, resulting in the displacement of PGE2 binding.
Features and Benefits
This compound is featured on the Prostanoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Storage Class
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
S J Lydford et al.
British journal of pharmacology, 112(1), 133-136 (1994-05-01)
1. Using a range of natural and synthetic prostanoid receptor agonists and antagonists, we have shown that the rat isolated trachea contains a heterogeneous population of prostaglandin receptor sub-types mediating both relaxation and contraction of the smooth muscle. Prostaglandin E2
K K Meja et al.
British journal of pharmacology, 122(1), 149-157 (1997-09-23)
1. The prostanoid receptor(s) that mediates inhibition of bacterial lipopolysaccharide (LPS)-induced tumour necrosis factor-alpha (TNF-alpha) generation from human peripheral blood monocytes was classified by use of naturally occurring and synthetic prostanoid agonists and antagonists. 2. In human monocytes that were
D F Woodward et al.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 11(3), 447-454 (1995-01-01)
The cloning of the genes that encode for prostaglandin (PG) receptors has resolved much of the complexity and controversy in this area by confirming the classification proposed by Coleman, et al. Two issues that remained unresolved were (1) the inability
S A Milne et al.
Prostaglandins, 49(4), 225-237 (1995-04-01)
A fourth PGE receptor subtype, the EP4 receptor, has recently been described in the pig saphenous vein (PSV). Similar to the EP2 receptor, it mediates relaxation and is linked to stimulation of adenylate cyclase. The aim of this study was
G C Smith et al.
The Journal of pharmacology and experimental therapeutics, 271(1), 390-396 (1994-10-01)
The purpose of this study was to determine which receptors mediate the dilator effects of prostaglandins (PGs) on the ductus arteriosus of the fetal rabbit. Isolated rings of the vessel from fetal New Zealand White rabbits were precontracted with indomethacin
Related Content
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service